Joe Mullings’ Post

Chairman & CEO / MedTech's Top Search Consultant / The Mullings Group Companies / Board Member / Angel Investor / Keynote Speaker

2mo

This upcoming Friday I will have my Year in Review - 2024 and I will discuss the evolving models in medtech that support the critical development of emerging technologies and the ability to bring those technologies to patients via acquisition, rollup into private equity, or entry into the public markets. One of those successful models is Shifamed that has developed a fascinating and successful playbook. Amr Salahieh and I recently discussed the unique structure of Shifamed companies and the benefits to the market.

5 Comments

Transcript

Another really new thing that happened to us is just literally the other day I got a call from Mike Deneen who runs a Taiga Cardiovascular and we treated the first set of patients for the mitral valve replacement company. So this is first in man and we're really excited. Things are looking really good, learning a lot really quick, but it's looking like it's meeting all of our expectations and maybe some more than that we didn't expect. So we're pretty thrilled about that and the construct of the companies. The chief of that I know I've been on campus and I mentioned this is they're all standalone turnkey companies. Sure. Well, while you know, I've seen a lot of incubators, a lot of accelerators. There's like there's a front door and the back door and there's there's it's own standing. Here's the keys. You bought it last week. I'm here if you need me. Good luck. Yeah, I mean, the idea is within days after transaction, the company belongs to a large corporate and they have everything to be functional. That team they did just acquired is continues to work. They don't need to be distracted. They have everything to do what they need to do. They have their clean rooms, they are indeed space, they equipment, anything, you name it for them to be successful. I mean, last transaction we did with. With the Biosense Webster, when they bought Rivera, you know, we were at 29 member team and they quickly grew to over 100 while they're simultaneously sort of setting up, taking their time doing a proper large scale production facility. But in the meantime, the facility in the Bay Area was able to produce what they needed for the early years of commercialization. So that's our model is that really we put a big effort into autonomy, independence of each company, the ability for them to take a risk to do what they need to do and. And be efficient, right? So we don't want them to be slowed down for any reason. We want them to do what's right for their particular company.

Daniel J. Kasprzyk, graphic

Daniel J. Kasprzyk

Currently Founder at Poba Medical, Symple Surgical and ExperiENT Medical

2mo

Joe Mullings the greatest incubator of its time was Advanced Cardiovascular Systems of the 80’s and early 90’s. The number of successful companies and technologies that ACS alumnus created for this industry is truly unheard of for a single company or breeding ground….Easilly worth multiple Billions of company value post ACS. Amr Salahieh is at the head of this class! Shifamed

Ryan Blasko, graphic

Vice President - Global Med Device Leader Building Companies and Careers at TMG

2mo

With large strategics looking for built to buy companies, and PE as well, this model is gaining significant traction in MedTech.

Our MedTech Lives, graphic

Our MedTech Lives

2mo

Looking forward to the2024 Review

Stephen Endres, graphic

Grow and Secure Your Wealth | Mission Capital Funds | Passive Income | Integrity, Transparency, Long-Term Focus

2mo

The evolving models in medtech are definitely shaping the future of healthcare.

Mike Moore, graphic

Partner @ The Mullings Group, Board Member, "24 in '24 Top Voices in Med Tech (MD+DI)", Host of The Bleeding Edge of Digital Health Podcast

2mo

Incredible model Amr has developed at Shifamed. Different from what Fred has built at Imperative Care…but some common themes none the less.

See more comments

To view or add a comment, sign in

More Relevant Posts

Ashkan Afkhami

Managing Director & Senior Partner | BCG X Global Health Care Leader, Board Member, F500 Operator, Entrepreneur, and Investor
4mo
Report this post
GenAI is opening up immense opportunities for #healthcare investors. From biopharma to medtech, investors are diving into data-driven innovations, supporting the ecosystem, and navigating new regulations. For those ready to embrace change, #GenAI is an unprecedented avenue for impact and growth. Read more here: https://on.bcg.com/3UD9lQz
1 Comment
Like Comment
To view or add a comment, sign in
Roshan A. Khan

Business Development @Baker Mckenzie
3mo
Report this post
Baker Mckenzie Partners Oren Livne, Julie Yeni and Julia Schieber, alongside Henrique Frizzo (Trench Rossi Watanabe) were delighted to present at the #Investibale Showcase alongside our special guest, Lilian Alcaraz (VP, Early Innovation Partnering at Johnson & Johnson Innovation, EMEA). The Master Licensing Class attended by over 100 delegates was designed for Biotech, Healthtech and Medtech companies and considered key trends impacting licensing deals, including M&A activity, policy and regulatory changes, new technologies such as AI. The interactive discussion from the delegates during the session was not only informative but gave us valuable opportunities to engage deeply with the many challenges and opportunities faced by organisations and the investors operating in this dynamic sector. Read more: https://bmcknz.ie/4eBmil7
Like Comment
To view or add a comment, sign in
Tom Revis

Manager, West Coast Account Management | Private Equity, Venture Capital, Mergers & Acquisitions
3mo
Report this post
🚨 The PitchBook Q3 2024 #Medtech Report is Live! 🚨 Our latest report highlights key trends, insights, and company updates in Medtech, plus exclusive market data. 📊 Key Takeaways: 💰 VC Funding: Q3 saw $3.2B in #VCFunding, steady with prior quarters. Element Biosciences’ $277M round now leads Medtech deals for 2024. 🏛️ Regulatory Updates: Limited impact expected from the US Election, but we’re watching LDT regulations and CMS coverage for Breakthrough Devices. 📈 Exits on the Rise: Successful IPOs (e.g., Tempus AI) and $100M+ acquisitions (Endotronix, Paragonix Technologies, Inc., and more) are boosting exit activity. 🤖 #SurgicalRobotics Surge: FDA approvals (CMR Surgical, Moon Surgical) and $360M+ YTD VC funding make this sector a top investment focus. Featured in this Report 🌟 #EmergingOpportunities: Wound care & smart implants. 🔎 Spotlight on Neuspera Medical Inc. (neuromodulation) and Earlens Corporation (hearing aids). 💻 Access the Full Report Clients can explore 3k+ companies and deals via the workspace and ACV + market map. #Medtech #Innovation #Healthcare #VentureCapital #Q32024

Q3 2024 Medtech Report | PitchBook

pitchbook.com
Like Comment
To view or add a comment, sign in
Iain McCulley (CMgr FCMI)

Building a value-first MedTech Community | Providing talent solutions for the most innovative, purpose driven & patient centric MedTech | Medical Device | Digital Health | Diagnostics & Healthcare organisations
10mo
Report this post
No surprises for guessing where this weeks Industry Insights starts... As well as another push for tomorrow's Inside MedTech, we have loads of incredibly exciting funding stories, major acquisition announcements and some innovation that could make a difference to so many. Links to all articles in the comments. Keep on making a difference! #medtech #insidemedtech #medtechnews #medtechinvestment

2 Comments
Like Comment
To view or add a comment, sign in
Cencora | Pharma solutions

35,256 followers
1mo
Report this post
Launching new, innovative therapies can be overwhelming for an emerging company, due to a range of decisions and barriers. Ahead of a successful launch, it’s important to work with a patient support partner who has extensive experience and vetted processes. Here are five key questions to ask as you navigate choosing a potential partner: https://ow.ly/xQfv50UJvf1
Like Comment
To view or add a comment, sign in
Javier "Jave" Castillo

VP of Business Development Large & Mid Pharma at IQVIA
4mo
Report this post
Learn how your #MedTech #Device #Diagnostic peers are transforming their commercial models with #IQVIA #CSO to introduce: · Greater agility · Drive referrals and growth · Increase profitability https://bit.ly/3BLbQJX

IQVIA United States

22,126 followers
4mo Edited

#MedTech innovations continue to drive life-changing, paradigm-shifting treatments. Learn how partnering with #IQVIA MedTech can bring the right mix of resources and deployment, backed by strong data-driven insights, to drive growth and optimize margins for your organization. Read this recent Fierce MedTech article by Javier "Jave" Castillo and Kirk Harmon: https://bit.ly/3BLbQJX
Like Comment
To view or add a comment, sign in
Thomas Earlam

Recruitment Consultant - HEOR, Market Access & Sales
11mo
Report this post
The LSX World Congress, a premier event in Europe that brings together CEOs, senior decision-makers, investors, and industry experts from the most innovative biopharma, medtech, and healthtech companies, is fast approaching us. Whether you’re interested in AI implementation in healthcare, seeking strategic alliances, or exploring investment opportunities, this conference provides just the platform and is a must-attend event for industry professionals! One panel to keep an eye on.. the impact of synergizing innovation - how Pharma & Biotech can collaborate to optimise AI applications. #lifesciences #LSXWorld #workingforyourtomorrow
Like Comment
To view or add a comment, sign in
IQVIA United States

22,126 followers
4mo Edited
Report this post
#MedTech innovations continue to drive life-changing, paradigm-shifting treatments. Learn how partnering with #IQVIA MedTech can bring the right mix of resources and deployment, backed by strong data-driven insights, to drive growth and optimize margins for your organization. Read this recent Fierce MedTech article by Javier "Jave" Castillo and Kirk Harmon: https://bit.ly/3BLbQJX
Like Comment
To view or add a comment, sign in
Nasser Sobh, MBA

Accounting and Consulting Professional Extraordinaire
2mo
Report this post
J.P. Morgan’s Q3 Medtech Report highlights record-breaking venture investments, robust M&A activity and the return of IPOs, signaling strong growth in 2024. Take a look at the latest trends driving innovation in medical devices, diagnostics and digital health. https://lnkd.in/diPv4wEf
Like Comment
To view or add a comment, sign in
BioT

3,997 followers
4mo
Report this post
Heading to the Investival Showcase next week? So are we! 😎 We’re excited to be in London on November 18th, joining over 1,000 attendees from the BioTech, HealthTech, and MedTech communities. This is a great chance to connect with innovators, investors, and industry leaders, all focused on advancing healthcare. Our CEO, Daniel Adler, will be there to discuss how BioT’s secure infrastructure for medical device clouds is helping deliver next-generation care. If you’re attending, let’s connect! Reach out or schedule a meeting to explore how we can collaborate to improve patient care. The link to schedule a meeting is in the comments. P.S. Want to know where we’re headed next? Follow us and like this post. #investival #biotech #medtech #healthtech #digitalhealth
1 Comment
Like Comment
To view or add a comment, sign in

Joe Mullings

53,179 followers

View Profile Connect

More from this author

Explore topics